Summaries of well being coverage protection from main information organizations
Researchers on the College of California San Diego, counting on toxicological testing as an alternative of self-reporting amongst individuals, discovered that the tempo of progress wasn’t as pronounced for kids confirmed to have used marijuana.
The San Diego Union-Tribune:
Marijuana Study Affirms Drug’s Negative Effect On Youth
A brand new UC San Diego research strengthens the rising physique of proof that marijuana use impacts adolescent mind growth. Researchers noticed slower features in cognitive checks that measured reminiscence, focus and pondering pace amongst center and excessive school-age children who used hashish when in comparison with those that abstained. (Sisson, 4/21)
On smoking and vaping —
The New York Times:
Proposed Lifetime Smoking Ban To Become Law In Britain
Britain goals to boost a “smoke-free era” by completely banning the sale or provide of tobacco and vape merchandise to anybody born in 2009 or after, with a invoice that was authorized by Parliament on Tuesday. The invoice applies to individuals presently 17 years outdated or youthful and goals to maintain them from ever choosing up the behavior of their lifetime. The proposal is predicted to quickly go into legislation after the ultimate formality of approval by King Charles III. (Livni, 4/21)
In different pharmaceutical information —
AP:
Purdue Pharma’s Sentence Date Is Postponed A Week To Let Opioid Victims Attend
A decide on Tuesday delayed the felony sentencing of OxyContin maker Purdue Pharma in an effort to permit victims to attend the court docket continuing in individual. U.S. District Decide Madeline Cox Arleo initially deliberate handy down the sentence Tuesday throughout a court docket listening to carried out solely by videoconferencing. However she stated she modified her thoughts after seeing some victims of the opioid disaster protesting outdoors her courthouse in Newark, New Jersey. She stated they need to be allowed to attend in individual, too, and moved the listening to to subsequent Tuesday. (Mulvihill, 4/22)
MedPage Today:
FDA Approves New Standalone Combo Pill For HIV
The FDA authorized islatravir-doravirine (Idvynso) as a standalone, single-tablet routine for treating HIV in virologically suppressed adults, Merck introduced on Tuesday. Approval stipulates use of the oral mixture in sufferers with HIV-1 who’re virologically suppressed on secure antiretroviral remedy (ART), haven’t any historical past of virologic therapy failure, and haven’t any identified substitutions related to doravirine resistance. Co-administration with different ART medicines will not be really helpful. (Rudd, 4/21)
Stat:
Roche Set To Take Its MS Drug To Regulators, But Safety Questions Loom
The Swiss drugmaker Roche on Tuesday introduced the newest knowledge for its experimental a number of sclerosis drug, setting the stage for the corporate to hunt approval for a medication that it believes can lower relapse charges and sluggish the progressive incapacity the illness causes. (Joseph, 4/21)
Stat:
Kyverna Therapeutics Therapy Improves Mobility In Stiff Person Syndrome Patients
A one-time, customized cell remedy from Kyverna Therapeutics improved mobility and lowered disabilities in sufferers with stiff individual syndrome, a uncommon, neurological autoimmune dysfunction, in accordance with research outcomes introduced Tuesday. (Feuerstein, 4/21)
Axios:
Amazon One Medical Launches National GLP-1 Weight-Loss Program
Amazon’s One Medical is rolling out a nationwide GLP-1 program as demand for weight-loss medicine surges, the corporate introduced Tuesday. The growth in medicine like Ozempic and Wegovy is reshaping weight problems care — but additionally exposing gaps in how sufferers are handled. (Tyko, 4/21)
